...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Presentation
6
Oct 24, 2017 11:18AM
1
Oct 25, 2017 09:02AM
2
Oct 26, 2017 10:24AM
5
Oct 26, 2017 12:13PM

Nov 02, 2017 03:38PM

Nov 02, 2017 04:29PM

Nov 03, 2017 10:49AM

Nov 03, 2017 10:58AM

Nov 03, 2017 12:07PM
2
Nov 03, 2017 03:45PM

HL - At the risk of sounding like a broken record, RVX-208 is in a double blinded Phase III trial and has been for the past 2 yrs. With a company like RVX that has limited funds(read that as never enough) this can be really boring. We are almost totally dependant on BETonMACE information to keep our interest for which there is almost none because it is a blinded trial. For RVX it's zzzzz time however the Zenith trial is not blinded so we are able to get a few nuggets of info along the way to keep our interest and hopes up. The number of nuggets from Zenith could and should be ramped up a little though. As BDAZ says in the previous post there is lots of positive info on apabetalone out, just not to much in the last couple of yrs.

tada

5
Nov 18, 2017 07:45PM
Share
New Message
Please login to post a reply